Bayer plans to discontinue sales of the Essure birth control implant in the United States, citing a decline in U.S. sales of the device.
The TAVR space is heavily dominated in the U.S. and Europe by Edwards Lifesciences and Medtronic, but Meril said there is enough room in the market for more players.
The Marlborough, MA-based company is set to swoop in and pick up Claret Medical, an embolic protection specialist, in a deal worth $270 million.
Viz.ai is the latest company in the artificial intelligence space to draw attention from investors and raised about $21 million in a series A round.
Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
Through its new MiniMed 670G performance guarantee program, Medtronic said it will provide flat-fee reimbursements up to $25,000 per pump over four years of qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
Baxter said it is evaluating other potential locations, including contract manufacturers, to support its supply needs if necessary.
The company asked the court to dismiss a negligence case involving St. Jude Medical's Riata ST lead, but a federal judge denied the motion, allowing the case to proceed.
Endologix promoted from within to fill the CEO seat. Will this strategy help the struggling EVAR company up its game?
MD+DI News Editor Amanda Pedersen talks about recent M&A trends in medtech and the attributes that make companies stand out as potential acquisition targets.
The San Francisco, CA-based company has raised $26.6 million in a series C round to help further commercialize its Accuryn Monitoring System.
Angiodynamics CEO Jim Clemmer assures investors that the company is ready and able to execute M&A opportunities, either in terms of divestitures or acquisitions.
At least one analyst sees a bright future for Nevro, even if the company is holding the short end of the stick at the conclusion of a longstanding patent dispute with Boston Scientific.